Published on March 12, 2014
MELANOMA THE MOST FATAL FORM OF SKIN CANCER firstname.lastname@example.org
MELANOMA • Incidence is increasing • Lifetime probability of developing melanoma • 1/37 men • 1/56 women • Five-year survival rates depend upon the stage of the disease at the time of diagnosis • Rare in children and adolescents email@example.com
RISK FACTORS • Genotype • Personal history of skin cancer • Family history • Atypical nevi • Common nevi • Phenotype • Sun exposure click firstname.lastname@example.org
SUN EXPOURE • Higher rates with extensive or repeated intense exposure to sunlight • Greater penetration of UV light into the skin results in a higher risk • Incidence is highest in equatorial areas and decreases proportionately with distance from the equator email@example.com
• Decrease in recreational sun exposure following the diagnosis of primary melanoma, can significantly diminish the chance of a second primary melanoma firstname.lastname@example.org
• UV-A versus UV-B irradiation • UV-A 320-400 nm • UV-B 290-320 nm • PUVA therapy (Psoralen) • Late increase in the risk of melanoma email@example.com
TIMING AND PATTERN OF SUN EXPOSURE • Nonmelanoma cancers are associated with cumulative sun exposure • Melanomas are associated with intense, intermittent sun exposure and sunburns firstname.lastname@example.org
• Tanning beds (since 1920) • Deep tan – status symbol • WHO (2009) UV-A from tanning beds as human carcinogen email@example.com
CLINICAL FEATURES • Superficial tumors that are confined to the epidermis • Horizontal or "radial" growth phase • “Vertical" growth phase firstname.lastname@example.org
• Subtypes • Superficial spreading • Nodular • Lentigo maligna melanoma • Acral lentiginous melanoma email@example.com
SUPERFICIAL SPREADING MELANOMA • The most common subtype • Over 60% are diagnosed as thin, highly curable tumors of less than 1 mm thickness • Can occur in any anatomic location • Variably pigmented macule or plaque with an irregular border, ranging from a few millimeters to several centimeters in diameter firstname.lastname@example.org
• Multiple shades of red, tan, brown, blue, black, gray, and white can be appreciated • Histologically • Asymmetric, poorly circumscribed, lack cellular maturation email@example.com
• In the radial phase of growth, there is haphazard growth of neoplastic melanocytes with single-cell spread throughout the layers of the epidermis • Transition to vertical growth phase occurs when the largest nest in the dermis exceeds that in the epidermis firstname.lastname@example.org
NODULAR MELANOMA • Vertical growth phase melanomas • 15 to 30 percent of all melanomas • Darkly pigmented, pedunculated or polypoid nodule • Histologically • Dermal growth occurs in isolation or, occasionally • Neoplastic cells within the dermal growth may appear epithelioid or spindled • Mitoses are frequent and often atypical email@example.com
LENTIGO MALIGNA MELANOMA • Most commonly arises in sun-damaged areas of the skin in older individuals • Begins as a freckle-like tan-brown macule • Transformation is slow • Once it is fully evolved, color variegation can be striking firstname.lastname@example.org
• Histologically • During the radial growth phase, the atypical melanocytes are usually polygonal in shape with hyperchromatic, angulated nuclei • Multinucleated giant melanocytes ("star-burst giant cells") may be present at the basal layer of the epidermis • The hallmark of the vertical growth phase is the formation of dermal nodules and fascicles that are larger than the epidermal component • Pleomorphic with variably hyperchromatic nuclei email@example.com
ACRAL LENTIGINOUS MELANOMA • The least common variant of radial growth phase melanomas • Fewer than 5 percent of all melanomas • Palmar, plantar, subungual, and occasionally, mucosal surfaces • Most common type of malignant melanoma among asians and dark-skinned individuals • Not all melanomas arising in acral sites are acral lentiginous melanomas firstname.lastname@example.org
• Dark brown to black, unevenly pigmented patch • Areas of regression manifest as foci of gray-white discoloration email@example.com
• Histologically • Lentiginous array of atypical melanocytes along the dermal- epidermal junction, with foci of confluent melanocytic growth • Invasive lesions are characterized by the presence of neoplastic single cells or nests in the dermis • Large, hyperchromatic, angulated melanocytes with scant cytoplasm firstname.lastname@example.org
DIAGNOSIS • The clinical recognition of melanoma may be challenging even for the most experienced dermatologist • Asymmetry • Irregular borders • Variegated color • Diameter >6mm • Recent change in a lesion email@example.com
ABCDE RULE • Asymmetry (if a lesion is bisected, one half is not identical to the other half) • Border irregularities • Color variegation (brown, red, black or blue/gray, and white) • Diameter ≥6 mm • Evolving: a lesion that is changing in size, shape, or color, or a new lesion firstname.lastname@example.org
THE REVISED GLASGOW SEVEN-POINT CHECKLIST • Major: • Change in size/new lesion • Change in shape • Change in color • Minor: • Diameter ≥7mm • Inflammation • Crusting or bleeding • Sensory change email@example.com
THE "UGLY DUCKLING" SIGN • A pigmented lesion that looks different from other surrounding lesions must be considered suspicious, even if it does not fulfill the ABCD criteria. firstname.lastname@example.org
DIFFERENTIAL DIAGNOSIS • Common melanocytic nevus • Atypical melanocytic nevus • Traumatized nevus • Blue nevus • Lentigo (ink spot) • Spitz nevus • Melanonychia striata email@example.com
• Pigmented basal cell carcinoma • Pigmented actinic keratosis • Seborrheic keratosis • Pyogenic granuloma • Cherry hemangioma • Dermatofibroma • Keratoacanthoma • Subungual hematoma firstname.lastname@example.org
MANAGEMENT OF PATIENTS WITH SUSPICIOUS SKIN LESIONS • Referral • Biopsy • Monitoring email@example.com
• Referral • A new mole appearing after the onset of puberty which is changing in shape, color, or size • A long-standing mole which is changing in shape, color, or size • Any mole which has three or more colors or has lost its symmetry • A mole which is itching or bleeding • Any new persistent skin lesion especially if growing, if pigmented or vascular in appearance, and if the diagnosis is not clear • A new pigmented line in a nail especially where there is associated damage to the nail • A lesion growing under a nail firstname.lastname@example.org
• Biopsy • Biopsy is necessary whenever melanoma is suspected. • An excisional biopsy that includes the entire lesion with 1 to 3 mm margins of normal skin and part of the subcutaneous fat should be performed whenever possible. • Incisional biopsy may be occasionally acceptable for very large lesions or for certain sites, including the face, palm or sole, ear, distal digit, or subungual lesions email@example.com
• Monitoring • Patients at increased risk of melanoma should have regular examinations once or twice a year • Australian Cancer Network recommends monthly skin self- examination and biannual full body skin examination by a clinician for high risk individuals firstname.lastname@example.org
STAGING • TNM STAGING email@example.com
PROGNOSTIC FACTORS • Primary tumor (T) • Tumor thickness • Mitotic rate • Ulceration • Lymphatic involvement (N) • Node classification • Satellite lesions and in transit metastases • Distant metastases (M) • Age • Gender • Anatomic firstname.lastname@example.org
INITIAL BIOPSY • Excisional biopsy • Incisional biopsy • Shave biopsy • Never appropriate for the following reasons • The lesion is likely to be inadequately excised, with residual tumor remaining at both the radial and deep margins. • Because only the superficial portion of the tumor is removed, shave biopsies results underestimate tumor thickness, a critical prognostic factor and determinant of treatment. • Fibrosis and scarring at the base of the biopsy site may obscure residual melanoma, making it impossible for a pathologist to identify tumor and accurately measure its thickness. email@example.com
WIDE LOCAL EXCISION • The definitive surgical treatment • The recommended width of the normal tissue around the lesion has progressively decreased as a result of multiple large clinical trials that have examined the impact of the surgical margin on the local recurrence rate • The thickness of the melanoma is a key factor in determining the stage of the lesion and the recommended margin of normal tissue to be resected. firstname.lastname@example.org
Study, author; year n Median follow-up Melanoma thickness Margi ns Local recurrence, (percent) Overall survival, percent World Health Organization Cascinelli, N; 1998 612 12 yrs 0-1 mm 1 cm 3/186 (1.6) 87 1.1-2 mm 1 cm 5/119 (4.2) 0-1 mm 3 cm 1/173 (0.6) 85 1.1-2 mm 3 cm 2/134 (1.5) Swedish Cohn-Cedarmark, G; 2000 989 11 yrs 0.8-2 mm 2 cm 3/476 (0.6) 79 5 cm 5/513 (1) 76 French Cooperative Group Khayat, D; 2003 326 16 yrs <2.1 mm 2 cm 1/181 (0.05) 87 5 cm 4/185 (0.2) 86 Melanoma Intergroup Trial Karakoussis, CP; 1996 468 8 yrs 1-4 mm 2 cm (2.1) 80 4 cm (2.6) 84 British Trial Thomas, JM; 2004 900 60 mos ≥2 mm 1 cm 15/453 (3.3) No significant difference3 cm 13/457 (2.8) email@example.com
WIDE LOCAL EXCISION • Thin melanomas • Resect melanomas <1 mm thick (T1) with a 1 cm margin of normal tissue • For melanomas 1 to 2 mm thick (T2 lesions), use a 2 cm margin of normal tissue if this is feasible without the need for a skin graft firstname.lastname@example.org
• Intermediate thickness melanomas • Primary melanomas between 2 and 4 mm thick (T3), 2 cm excision margin email@example.com
• Thick melanomas • Thick melanomas (ie, those >4 mm), 2cm excision margin firstname.lastname@example.org
• In situ melanomas • There are no data from randomized trials to define the optimal extent of surgical resection. • Retrospective data support the routine use of 0.5 cm margins email@example.com
LYMPH NODE METASTASIS • 20 percent of clinically node-negative patients have metastatic involvement • 20 percent of those with clinically positive nodes are pathologically negative firstname.lastname@example.org
CLINICALLY APPARENT REGIONAL LYMPH NODES • Therapeutic lymphadenectomy • Elective lymph node dissection • Sentinel lymph node biopsy email@example.com
THERAPEUTIC LYMPHADENECTOMY • Therapeutic lymphadenectomy is the preferred treatment for cytologically or pathologically proven regional lymph node involvement • Complete regional lymphadenectomy is necessary rather than partial dissection or sampling firstname.lastname@example.org
ELECTIVE LYMPH NODE DISSECTION • ELND for clinically node-negative patients is controversial despite a number of trials evaluating this approach • There may be subgroups of patients who benefit from ELND, but consensus is lacking on this issue. email@example.com
SENTINEL LYMPH NODE BIOPSY • If the sentinel lymph nodes are not involved, the entire basin should be free of tumor • Completion lymph node dissection is used for patients with tumor involvement of the sentinel lymph node firstname.lastname@example.org
• Patient selection • SLNB is indicated for tumors ≥1 mm thick. • Tumors less than 1 mm in thickness have less than a 10 percent likelihood of nodal metastases, and SLNB is not routinely indicated. However, certain high-risk features (ulceration, a mitotic rate ≥1 per mm2) are associated with a higher rate of lymph node metastasis, thereby justifying the use of SLNB • Tumors >4 mm thick have a 65 to 70 percent risk of distant metastasis. However, SLNB may still provide important prognostic information. email@example.com
SURVEILLANCE AFTER TREATMENT • The primary objective of follow-up in patients with melanoma is to identify potentially curable locoregional recurrences and second primary cancers. firstname.lastname@example.org
• A routine physical examination, including a full skin assessment and palpation of the regional lymph nodes, which should be repeated at least yearly • The frequency of such evaluation should be increased in patients at high risk of recurrence • Imaging studies should be done if symptoms are present; the value of routine imaging is uncertain email@example.com
Calcification Inhibitors in CKD and Dialysis Patients
Das maligne Melanom (von gr. μέλας „schwarz“), auch kurz Melanom, Melano(zyto)blastom oder schwarzer Hautkrebs (engl.: [malignant] melanoma ...
Melanoma, also known as malignant melanoma, is a type of cancer that develops from the pigment-containing cells known as melanocytes. Melanomas typically ...
Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas ...
What is melanoma? Melanoma is usually, but not always, a cancer of the skin. It begins in melanocytes – the cells that produce the pigment melanin that ...
Comprehensive physician-reviewed information about melanoma, including warning sign photos, treatment, risk factors, and prevention guidelines.
Get information on melanoma (skin cancer) signs, diagnosis, treatment, prognosis, and symptoms. Learn about staging, early detection, treatment side ...
El melanoma es causado por cambios en las células llamadas melanocitos. Estas células producen un pigmento en la piel llamado melanina. La melanina es ...
Information about treating intraocular (eye) melanoma, clinical trials, and other topics from the National Cancer Institute.
Stages of melanoma diagnosis. Staging melanoma is the process used to describe the extent of the disease. The doctor will take into account the tumor ...
Learn about melanoma skin cancer from early detection, support resources, treatment decisions, staying well after and more.